Program
lumateperone
Also written as “Lumateperone”, “ITI-007” and “Lumateperone high dose”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Autism Spectrum Disorder · Alzheimer Disease, led by Johnson & Johnson.
Furthest: phase 3, since Oct 31, 201425 company-led studies, 6 open or runningNext primary completion: Apr 5, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 256 open or running | phase 3since Oct 31, 2014 | Dec 16, 2011 | Apr 5, 2027phase 3 · NCT05850689 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Dec 16, 2011.
- Aug 11, 2017Phase 3 study in Bipolar DisorderNCT03249376 · 381 enrolled · United States, Bulgaria, Colombia and more
- Feb 24, 2020Phase 3 study in Bipolar DisorderNCT04285515 · 488 enrolled · United States, Bulgaria, Russian Federation and more
- Feb 26, 2021Phase 1 study in SchizophreniaNCT04779177 · 26 enrolled · United States
- Jun 30, 2021Phase 3 study in SchizophreniaNCT04959032 · 592 enrolled · United States, Bulgaria, Poland and more
- Jul 22, 2021Phase 3 study in Depressive Disorder, MajorNCT04985942 · 485 enrolled · United States, Bulgaria, Czechia and more
- Sep 20, 20212 phase 3 studies in Depressive Disorder, MajorNCT05061719, NCT05061706
- Apr 28, 2023Phase 3 study in Depressive Disorder, MajorNCT05850689 · 470 planned · United States, Bulgaria, France and more
- Jan 19, 2024Phase 3 study in SchizophreniaNCT06229210 · 300 planned · United States, Colombia, Serbia
- Apr 15, 2024Phase 3 study in Bipolar DisorderNCT06372964 · 384 planned · United States, Colombia, India and more
- Jun 12, 20242 phase 3 studies in Bipolar DisorderNCT06462612, NCT06462586
- Aug 14, 2024Phase 1 study in Autism Spectrum DisorderNCT06557902 · 33 enrolled · United States
- Oct 2, 2024Phase 1 study in SchizophreniaNCT06627413 · 52 enrolled · United States
- Nov 13, 20242 phase 3 studies in Irritability Associated With Autism Spectrum DisorderNCT06690398, NCT06706674
- Jul 30, 2026Phase 3 study in Depressive Disorder, MajorNCT07747389 · 585 planned
Ahead
- Apr 5, 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT05850689
- Jun 21, 2027Primary completion: phase 3 study in Irritability Associated With Autism Spectrum DisorderNCT06706674
- Jun 21, 2027Primary completion: phase 3 study in Irritability Associated With Autism Spectrum DisorderNCT06690398
- Sep 20, 2029Primary completion: phase 3 study in Depressive Disorder, MajorNCT07747389
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor”ChEMBL 37, by rule
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07747389Depressive Disorder, Major | 3 | Not yet recruiting | Sep 20, 2029 | 585 |
| NCT06706674Irritability Associated With Autism Spectrum Disorder · United States | 3 | Recruiting | Jun 21, 2027 | 160 |
| NCT06690398Irritability Associated With Autism Spectrum Disorder · United States, Serbia | 3 | Recruiting | Jun 21, 2027 | 160 |
| NCT06627413Schizophrenia · United States | 1 | Completed | Nov 20, 2025 | 52 |
| NCT06557902Autism Spectrum Disorder · United States | 1 | Completed | Nov 26, 2025 | 33 |
| NCT06462612Bipolar Disorder · United States, Bulgaria, Romania and more | 3 | Completed | May 15, 2026 | 351 |
| NCT06462586Bipolar Disorder · United States, Bulgaria, Croatia and more | 3 | Completed | Feb 24, 2026 | 354 |
| NCT06372964Bipolar Disorder · United States, Colombia, India and more | 3 | Recruiting | Oct 31, 2031 | 384 |
| NCT06229210Schizophrenia · United States, Colombia, Serbia | 3 | Recruiting | Apr 28, 2032 | 300 |
| NCT05850689Depressive Disorder, Major · United States, Bulgaria, France and more | 3 | Recruiting | Apr 5, 2027 | 470 |
| NCT05061719Depressive Disorder, Major · United States, Bulgaria, Czechia and more | 3 | Completed | Oct 14, 2024 | 812 |
| NCT05061706Depressive Disorder, Major · United States, Argentina, Bulgaria and more | 3 | Completed | Apr 12, 2024 | 480 |
| NCT04985942Depressive Disorder, Major · United States, Bulgaria, Czechia and more | 3 | Completed | Feb 22, 2024 | 485 |
| NCT04959032Schizophrenia · United States, Bulgaria, Poland and more | 3 | Completed | Jul 25, 2024 | 592 |
| NCT04779177Schizophrenia · United States | 1 | Completed | Jul 30, 2022 | 26 |
| NCT04285515Bipolar Disorder · United States, Bulgaria, Russian Federation and more | 3 | Completed | Nov 30, 2022 | 488 |
| NCT03249376Bipolar Disorder · United States, Bulgaria, Colombia and more | 3 | Completed | Mar 1, 2019 | 381 |
| NCT02817906Aberrant Motor Behavior in Dementia · United States | 3 | Terminated | Jan 30, 2019 | 177 |
| NCT02600507Bipolar Disorder · United States, Bulgaria, Russian Federation and more | 3 | Completed | Jul 2, 2020 | 529 |
| NCT02600494Bipolar Disorder · United States | 3 | Completed | Jan 28, 2019 | 554 |
| NCT02469155Schizophrenia · United States | 3 | Completed | Aug 2016 | 696 |
| NCT02288845Schizophrenia · United States | 2 | Completed | Jul 2015 | 14 |
| NCT02282761Schizophrenia · United States | 3 | Completed | Jul 2015 | 450 |
| NCT02078310Alzheimer Disease · United States | 2 | Completed | Aug 2014 | 35 |
| NCT01499563Schizophrenia · United States | 2 | Completed | Aug 2013 | 335 |
How it is read
Names in the registry
- “Lumateperone”, 11 entries
- “ITI-007”, 7 entries
- “Lumateperone high dose”, 2 entries
- “Lumateperone low dose”, 2 entries
- “Lumateperone 42 mg”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 8 studies
- Bipolar Disorder, 7 studies
- Depressive Disorder, Major, 5 studies
- Autism Spectrum Disorder, 3 studies
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.